Timing is everything: new trial tests best duration of hormone therapy before breast cancer surgery

This study looks at how long hormone-blocking therapy given before surgery (neoadjuvant endocrine therapy) affects breast cancer in people with early-stage disease. About 90 participants will receive therapy for different lengths of time, from weeks up to a year. Researchers want to see if longer treatment leads to clearer surgical margins and better tumor response, and to develop a score that predicts outcomes.